1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
NutraLife BioSciences, Inc.

NutraLife BioSciences, Inc.

NLBS
NutraLife BioSciences, Inc.US flagOther OTC
0.00
USD
- -
- -
17,662.00Market Cap
NutraLife BioSciences, Inc.
NLBS
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
FRC
0.01
0.03
- -
0.01
0.01
0.02
0.04
0.02
0.01
- -
- -
Revenue per Share
-0.03
-0.11
-0.1
-0.09
-0.06
-0.33
-0.02
-0.04
-0.02
-0.04
-0.03
Basic EPS, GAAP
-0.02
-0.06
-0.06
-0.04
-0.02
-0.02
-0.01
-0.04
-0.01
- -
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.05
-0.15
-0.22
-0.3
-0.27
-0.46
-0.4
-0.34
-0.29
-0.29
-0.29
Book Value per Share
-0.01
- -
-0.04
-0.01
-0.06
0.01
0.01
0.01
- -
-0.01
-0.02
Tangible Book Value per Share
15
18
22
23
34
72
87
113
146
165
175
Basic Weighted Avg Shares
- -
1
- -
- -
- -
2
4
2
1
1
1
Sales/Revenue/Turnover
-306.34
-337.32
-2,618.18
-860.82
-662.57
-1,133.39
-51.36
-159.14
-157.12
-713.77
-385.88
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-2
-2
-2
-2
-24
-2
-4
-3
-6
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-306.34
-348.52
-3,333.2
-1,083.03
-931.57
-1,319.94
-55.9
-187.82
-230.13
-929.99
-783.65
Profit Margin (%)
- -
- -
-1
- -
-2
- -
- -
-2
-3
-5
-4
Working Capital
- -
- -
- -
- -
- -
- -
- -
1
1
- -
- -
LT Debt
- -
- -
-1
- -
-2
1
1
2
- -
-1
-2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'22
Jun'22
Sep'22
ST Debt
3
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
174
177
177
Market Capitalization
14
11
12

Working Capital

FRC

•

in mil. unless spec.
Mar'22
Jun'22
Sep'22
Total Current Assets
- -
- -
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
4
Payables & Accruals
1
1
2
ST Debt
3
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-86.15%
-336.63%
Free Cash Flow
- -
69.96%
-62.05%
Net Income, GAAP
- -
220.31%
101.65%
Sales/Revenue/Turnover
- -
133.63%
-50.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
1
- -
- -
1
2021
- -
- -
- -
- -
1
2022
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
-0.01
- -
- -
- -
-0.02
2021
-0.02
-0.01
- -
- -
-0.04
2022
-0.01
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Similar Companies
Toho Holdings Co., Ltd. (8129.T)
VIVO Cannabis Inc. (VVCIF)
Pharma Foods International Co., Ltd. (2929.T)
Hua Medicine (Shanghai) Ltd. (2552.HK)
Tilray Brands, Inc. (2HQ.DE)
BioELife Corp. (LITH)
Business
NutraLife BioSciences, Inc. is a biotechnology company specializing in the development, manufacture, and distribution of nutraceutical, dietary, wellness, and cannabidiol (CBD) products. Its core product offerings include cannabinoid-rich hemp oil derived from industrial hemp; CBD tinctures; topical lotions and oils for pain and inflammation relief; face creams; massage oils; nutraceutical sprays with added CBD; pet care products; skincare; and sanitizer products. The company also develops performance-enhancing beverages, immunity boosters, and pharmaceutical-grade health solutions. NutraLife operates primarily in the United States and distributes its products through its website, private label partnerships, online retailers, and retail outlets. Founded in 2010 and headquartered in Coconut Creek, Florida, NutraLife BioSciences formerly operated as NutraFuels, Inc. until a name change in March 2019. Recent major developments include strategic partnerships and joint ventures such as an agreement with Emergent Health Corporation for co-production and co-marketing of regenerative and health-related nutraceutical products. NutraLife has expanded its product portfolio with launches like the NutraHempCBD micro shot line targeting sleep, pain, stress, weight, and energy management, and performance products such as Cock Shot and Nitric Pro Shot that focus on natural nitric oxide boosters for stamina and blood flow enhancement. The company also offers pharmaceutical-grade solutions accessible via telehealth, including GLP-1 medications for weight loss, under the Vitalis Rx brand. Additionally, NutraLife has established NutraDerma Technologies, a subsidiary commercializing patented natural dermal mosquito patches and aims to develop further nutraceutical skin patches leveraging its acquired patent technology. NutraLife BioSciences markets its products with a science-backed approach emphasizing in-house formulation, manufacturing control, and regulatory compliance. Its customer base includes health-conscious individuals, wellness-focused consumers, and pet owners across the U.S. The company has also pursued vertical integration with licenses to grow and process industrial hemp in Wisconsin to optimize cost efficiency in raw material sourcing. Key executives include founder and CEO Edgar Ward. NutraLife BioSciences continues to evolve as a multifaceted life sciences company with a focus on innovation in nutraceutical, skincare, and cannabinoid wellness sectors.

Company News

APIChatGPT

  • globenewswire.com

    NutraLife Biosciences Inc. (NLBS) Announces the Company's Financial Fully Reporting Status